Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671496 · ClinicalTrials.gov registry record · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
A Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06671496: Recruiting Phase 3 study of Psoriatic Arthritis, sponsored by Takeda.
NCT06671496 is a Phase 3 study of Psoriatic Arthritis that is actively recruiting participants, run by Takeda. The registered enrollment target is 600 participants, below the 840-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06671496, a Phase 3 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The participants will be treated with either zasocitinib, or placebo. Participants will be in the study for up to 60 weeks.
Primary Outcome
ACR responses are the numerical measurement of improvement in multiple disease assessment criteria. It is a composite clinical outcome assessment (COA) measure that includes both clinician-reported outcome assessments (ClinROs) and patient-reported outcomes (PROs). An ACR20 response is defined as: greater than or equal to (\>=) 20 percent (%) improvement from baseline in both swollen joint count 66 joints (SJC66) and tender joint count 68 joints (TJC68), and \>=20% improvement from baseline in 3
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zasocitinib
Study Locations (20)
Florida
- RASF- Clinical Research Center - Boca Raton
- Direct Helpers Medical Center - Hialeah
- IRIS Research and Development | Plantation, FL - Plantation
- BayCare Medical Group - St. Petersburg
Arizona
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Mesa
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Phoenix
- Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ - Tucson
Texas
- AARR- Lone Star Arthritis & Rheumatology Associates - Fort Worth
- Biopharma Informatic | Hassan - Houston
- Advanced Rheumatology of Houston - The Woodlands - The Woodlands
California
- Biovin Enterprises LLC dba Medvin Clinical Research | Covina, CA - Covina
Georgia
- North Georgia Rheumatology Group PC - Lawrenceville
Illinois
- Clinic of Robert Hozman - Skokie
Kentucky
- Graves Gilbert Clinic - Bowling Green
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2028-01-26 |
| Phase | Phase 3 |
What NCT06671496 shows while recruiting
NCT06671496 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 840-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06671496 names 20 study sites across 13 states, led by Florida, Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT06671496 about?
NCT06671496 is a clinical study titled "A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines". Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. Th...
What is the current status of trial NCT06671496?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-03-10. Estimated completion is 2028-01-26.
What conditions does trial NCT06671496 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
What interventions are being tested in trial NCT06671496?
The interventions under investigation include: Placebo (DRUG), Zasocitinib (DRUG).
Who is sponsoring clinical trial NCT06671496?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671496 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06671496's enrollment target sits among peer trials
600 14th of 48 higher than 35 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
RECRUITING · Phase 3
-
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
RECRUITING · Phase 3
-
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI